Welcome to our dedicated page for Zymeworks SEC filings (Ticker: ZYME), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Zymeworks's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Zymeworks's regulatory disclosures and financial reporting.
Zymeworks Inc. director Brian N. Cherry filed an initial ownership report stating that he does not beneficially own any of the company’s securities. As of January 12, 2026, the filing shows zero non-derivative shares of Zymeworks Inc. held and no derivative securities, such as options or warrants, beneficially owned. The filing is made as a Form 3, which discloses a director’s starting ownership position when they become subject to insider reporting rules.
Zymeworks Inc.'s EVP & Chief Medical Officer, Jeffrey T. L. Smith, reported the vesting of 17,666 restricted stock units (RSUs) on January 12, 2026, which converted into the same number of common shares at $0.00 per share. These RSUs were part of a grant made on January 10, 2025 that vests in three equal annual installments, with each RSU delivering one share of common stock upon vesting.
On the same date, 9,310 common shares were sold at a weighted average price of $22.6735 solely to cover tax withholding and related fees under mandatory “sell to cover” provisions, and not as a discretionary sale. After these transactions, Smith beneficially owned 26,708 common shares and 35,334 RSUs, all reported as directly held.
Zymeworks Inc. director Gregory Austin Ciongoli reported new equity awards on a Form 4. On January 12, 2026, he was granted stock options covering 11,500 shares of common stock at an exercise price of $23.16 per share. These options vest on January 12, 2027 and expire on January 11, 2036.
He also received 7,700 restricted stock units (RSUs) on the same date. Each RSU represents the right to receive one share of common stock upon vesting, and these RSUs vest on January 12, 2027. All reported derivative holdings are shown as directly owned, and the filing reflects awards being acquired rather than any sale of shares.
Zymeworks Inc. director Kelvin Neu reported new equity awards in a Form 4 dated January 12, 2026. He was granted 11,500 stock options with an exercise price of $23.16 per share and 7,700 restricted stock units (RSUs), all held as direct beneficial ownership.
The stock options and RSUs both vest on January 12, 2027. Each RSU gives the right, upon vesting, to receive one share of Zymeworks common stock. These transactions reflect equity compensation to a board member rather than open-market buying or selling.
Zymeworks Inc. reported that director Robert E. Landry received new equity awards. On January 12, 2026, he was granted stock options to buy 11,500 shares of common stock at an exercise price of $23.16 per share. These options vest on January 12, 2027 and expire on January 11, 2036, leaving him with 11,500 derivative securities beneficially owned after the grant.
On the same date, he was also granted 7,700 restricted stock units (RSUs), each representing the contingent right to receive one share of common stock upon vesting. These RSUs vest on January 12, 2027, and 7,700 derivative securities are shown as beneficially owned directly following the transactions.
Zymeworks Inc. director Alessandra Cesano received new equity awards, including stock options and restricted stock units. On January 12, 2026, she was granted stock options covering 11,500 shares of common stock and 7,700 restricted stock units. The footnotes state that the options vest on January 12, 2027 and that each RSU converts into one share of common stock upon vesting, with the RSUs also vesting on January 12, 2027. These awards are reported as directly owned following the transactions.
Zymeworks Inc. director Carlos Campoy reported new equity awards. On January 12, 2026 he received stock options covering 11,500 shares of common stock at an exercise price of $23.16 per share, which vest on January 12, 2027. He also received 7,700 restricted stock units, each representing one share of common stock, with the RSUs vesting on January 12, 2027. Following these awards, he directly holds 11,500 stock options and 7,700 RSUs in the company.
Zymeworks Inc. director Susan Mahony reported new equity awards. On January 12, 2026, she was granted stock options covering 11,500 shares of Zymeworks common stock with an exercise price of $23.16 per share. These options vest on January 12, 2027 and are scheduled to expire on January 11, 2036.
She was also granted 7,700 restricted stock units (RSUs) on the same date. Each RSU represents the right to receive one share of common stock upon vesting, and all 7,700 RSUs vest on January 12, 2027. Both the options and RSUs are reported as directly owned by Mahony.
Zymeworks Inc. Chief Scientific Officer Paul Andrew Moore reported multiple equity transactions on January 12, 2026. One third of a prior restricted stock unit (RSU) grant vested, resulting in 17,666 shares of common stock, and 9,560 shares were sold at a weighted average price of $22.6735 solely to cover tax withholding and related fees under a mandatory sell-to-cover provision. After these transactions, he directly held 48,497 shares of common stock.
On the same date, Moore received new equity awards, including 70,000 stock options with a $23.16 exercise price that vest 25% after one year and the rest in 36 monthly installments. He was also granted 47,000 RSUs vesting in four equal annual installments and 66,000 performance stock units, representing the maximum shares that may be earned based on total shareholder return goals over a three-year period ending January 12, 2029, subject to continued service.
Zymeworks Inc. Chair and CEO Kenneth Galbraith reported equity award activity and a tax-related share sale. On January 12, 2026, 64,000 restricted stock units vested and were settled into common shares at $0.00, and 30,424 common shares were sold at a weighted average price of $22.6735 solely to cover tax withholding and fees under mandatory “sell to cover” provisions. After these transactions, he directly held 226,842 common shares.
On the same date, he received new equity awards: a stock option for 216,000 shares at an exercise price of $23.16 expiring on January 11, 2036, which vests 25% after one year and monthly thereafter; a new RSU grant of 144,000 shares vesting in four equal annual installments; and performance stock units covering up to 222,000 shares tied to total shareholder return goals over a three-year period ending January 12, 2029, with 50%–200% of a 111,000-target range potentially earned.